Phase ii study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: Results of the French Genito-Urinary Tumor Group (GETUG) P01 trial

Annals of Oncology

Volumn 22, Issue 11, 2011, Pages 2476-2481

  Flechon A ^a   Pouessel, D ^b   Ferlay, C ^a   Perol, D ^a   Beuzeboc, P ^c   Gravis, G ^d   Joly, F ^e   Oudard, S ^f   Deplanque, G ^g   Zanetta, S ^h   Fargeot, P ^h   Priou, F ⁱ   Droz, J P ⁱ   Culine, S ^j  

^a CENTRE LÉON BÉRARD   (France)

^b CENTRE VAL D AURELLE   (France)

^c INSTITUT CURIE   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e CENTRE FRANÇOIS BACLESSE   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g SAINT JOSEPH HOSPITAL   (France)

^h CENTRE GEORGES FRANÇOIS LECLERC   (France)

ⁱ CHD Les Oudairies   (France)

^j HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

Chemotherapy; Chromogranin A; Metastatic castration resistant prostate cancer; Neuron specific enolase; Visceral metastases

Indexed keywords

CARBOPLATIN; CHROMOGRANIN A; ETOPOSIDE; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; DIFFERENTIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROENDOCRINE DIFFERENTIATION; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL DIFFERENTIATION; CHROMOGRANIN A; DISEASE-FREE SURVIVAL; ETOPOSIDE; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; NEUROENDOCRINE CELLS; ORCHIECTOMY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 80155163956     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr004     Document Type: Article

References (25)

1. Loblaw DA, Mendelson DS, Talcott JA et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgensensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004; 22(14): 2927-2941.
2. Palmgren JS, Karavadia SS, Wakefield MR. Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 2007; 34(1): 22-29.
3. Helpap B, Kollermann J. Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch 1999; 434(5): 385-391.
4. Brawn PN, Speights VO. The dedifferentiation of metastatic prostate carcinoma. Br J Cancer 1989; 59(1): 85-88.
5. Helpap B, Kollermann J, Oehler U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol Int 1999; 62(3): 133-138.
6. Sciarra A, Cardi A, Dattilo C et al. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Int J Clin Pract 2006; 60(4): 462-470.
7. Abrahamsson PA, Wadstrom LB, Alumets J et al. Peptide-hormone- and serotonin-immunoreactive cells in normal and hyperplastic prostate glands. Pathol Res Pract 1986; 181(6): 675-683.
8. Nakada SY, di Sant'Agnese PA, Moynes RA et al. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 1993; 53(9): 1967-1970.
9. Krijnen JL, Bogdanowicz JF, Seldenrijk CA et al. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997; 158(1): 171-174.
10. di Sant'Agnese PA, Cockett AT. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996; 78(2): 357-361.
11. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007; 14(3): 531-547.
12. Cussenot O, Villette JM, Valeri A et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996; 155(4): 1340-1343.
13. Berruti A, Dogliotti L, Mosca A et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000; 88(11): 2590-2597.
14. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513-1520.
15. Tannock IF, de WR, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502-1512.
16. Mitry E, Baudin E, Ducreux M et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81(8): 1351-1355.
17. Fjallskog ML, Granberg DP, Welin SL et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001; 92(5): 1101-1107.
18. Smith DC, Chay CH, Dunn RL et al. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer 2003; 98(2): 269-276.
19. Loriot Y, Massard C, Gross-Goupil M et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009; 20(4): 703-708.
20. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005; 47(2): 147-155.
21. Hirano D, Okada Y, Minei S et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004; 45(5): 586-592.
22. Papandreou CN, Daliani DD, Thall PF et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized smallcell carcinoma of the prostate. J Clin Oncol 2002; 20(14): 3072-3080.
23. Culine S, El Demery M, Lamy PJ et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007; 178(3 Pt 1): 844-848.
24. Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer. 2010 http://clinicaltrials.gov/ct2/show/NCT00514540ClinicalTrials.govIdentifier:NCT00514540.
25. Huang J, Wu C, di Sant'Agnese PA et al. Function and molecular mechanisms of neuroendocrine cells in prostate cancer. Anal Quant Cytol Histol 2007; 29(3): 128-138.